Briefs & Reports

For the past decade, pharmaceutical companies have increasingly used voluntary licenses to allow generic production of patented antiretroviral drugs for People Living with HIV/AIDS in poor countries. However, these licenses have not been pursued optimally from a public health standpoint. This paper will comment on the current efforts of global health institutions and propose a…

Examination of the potential benefit, if any, of Aurobindo’s decision to opt out of the MPP-Gilead license for TDF.

We prepared the following analysis as a response to claims made by the MPP about its economic benefits.

A leaked U.S. paper recently circulated to countries negotiating the TransPacific Partnership Agreement (TPPA) outlines the U.S. argument for eliminating “pre-grant opposition,” an important tool for preventing patent applicants from gaining patent monopolies based on weak or erroneous information, for improving the quality and efficiency of patent office examinations, and for safeguarding access to medicines.

This report focuses on the HIV drug patent landscape in China. The patents included this landscape include key ARV patents that are likely to have a bearing on procurement decisions in China.

This discussion paper was commissioned by the Indian Network for People Living with HIV/AIDS (INP+) to address the feasibility of introducing second-line ART into NACO’s public-sector treatment programme.

Radhakrishnan and Abraham, Indian Medical Parliamentarians Forum

Using examples of medicines that are already on the market, and some which do not yet have marketing approval in India, we attempt to demonstrate how the current proposal of a three-year data exclusivity period would impact access to these medicines.